1. Home
  2. BEAM vs BV Comparison

BEAM vs BV Comparison

Compare BEAM & BV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • BV
  • Stock Information
  • Founded
  • BEAM 2017
  • BV 1939
  • Country
  • BEAM United States
  • BV United States
  • Employees
  • BEAM N/A
  • BV N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • BV Business Services
  • Sector
  • BEAM Health Care
  • BV Consumer Discretionary
  • Exchange
  • BEAM Nasdaq
  • BV Nasdaq
  • Market Cap
  • BEAM 1.7B
  • BV 1.5B
  • IPO Year
  • BEAM 2020
  • BV 2018
  • Fundamental
  • Price
  • BEAM $17.46
  • BV $14.71
  • Analyst Decision
  • BEAM Strong Buy
  • BV Buy
  • Analyst Count
  • BEAM 10
  • BV 7
  • Target Price
  • BEAM $48.56
  • BV $17.82
  • AVG Volume (30 Days)
  • BEAM 2.4M
  • BV 872.6K
  • Earning Date
  • BEAM 08-05-2025
  • BV 08-06-2025
  • Dividend Yield
  • BEAM N/A
  • BV N/A
  • EPS Growth
  • BEAM N/A
  • BV N/A
  • EPS
  • BEAM N/A
  • BV 0.12
  • Revenue
  • BEAM $60,272,000.00
  • BV $2,698,700,000.00
  • Revenue This Year
  • BEAM N/A
  • BV $1.19
  • Revenue Next Year
  • BEAM $17.18
  • BV $3.14
  • P/E Ratio
  • BEAM N/A
  • BV $123.31
  • Revenue Growth
  • BEAM N/A
  • BV N/A
  • 52 Week Low
  • BEAM $13.53
  • BV $11.81
  • 52 Week High
  • BEAM $35.25
  • BV $18.89
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 39.16
  • BV 37.19
  • Support Level
  • BEAM $16.65
  • BV $14.52
  • Resistance Level
  • BEAM $21.40
  • BV $15.82
  • Average True Range (ATR)
  • BEAM 1.00
  • BV 0.42
  • MACD
  • BEAM -0.35
  • BV -0.12
  • Stochastic Oscillator
  • BEAM 13.89
  • BV 12.89

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About BV BrightView Holdings Inc.

BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.

Share on Social Networks: